GE HealthCare Price Targets Raised to $85 and $94 on Strong Q4, 12% Upside
On February 5, Morgan Stanley raised GE HealthCare’s price target from $80 to $85 after fourth-quarter results topped forecasts and improved the risk-reward profile. Piper Sandler lifted its target from $91 to $94 on January 30, noting nearly 12% upside and a robust hospital CapEx-driven order backlog.
1. Analyst Price Target Raises
Morgan Stanley on February 5 increased its price target for GE HealthCare from $80 to $85 with an Equal Weight rating, citing stronger fourth-quarter results and an improved risk-reward profile. On January 30, Piper Sandler raised its target from $91 to $94 and maintained an Overweight rating, highlighting roughly 12% upside potential.
2. Strong Q4 Performance and Order Backlog
GE HealthCare’s fourth-quarter revenue and earnings exceeded consensus, driven by healthy demand across imaging and diagnostics. A recent hospital capital expenditure survey underpins a robust order backlog, signaling sustained revenue visibility for upcoming quarters.
3. Business Segments and Growth Drivers
The company’s operations span Advanced Visualization Solutions, Imaging, Patient Care Solutions and Pharmaceutical Diagnostics, offering precision care products and services. Strength in mobile imaging systems and PDx consumables positions GE HealthCare to capture increased hospital spending and diagnostic volume growth.